Quality of adjuvant CMF chemotherapy for node-positive primary breast cancer: a population-based study

M Schaapveld; EGE de Vries; WTA van der Graaf; R Otter; PHB Willemse

doi:10.1007/s00432-004-0583-6

Quality of adjuvant CMF chemotherapy for node-positive primary breast cancer: a population-based study

M Schaapveld^*, EGE de Vries, WTA van der Graaf, R Otter, PHB Willemse

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

6 Citations (Scopus)

Abstract

Purpose: Adjuvant 'classical' oral cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) has long been the mainstay of adjuvant chemotherapy for premenopausal breast cancer patients. The Comprehensive Cancer Center North Netherlands (CCCN) breast cancer working group performed a retrospective audit of treatment guideline adherence and quality of CMF in hospitals in the CCCN area. Methods: The CMF treatment data of 251 consecutive axillary lymph node-positive breast cancer patients 3 patients/year (P=0.014) were treated by one specialist or >10 patients classified for adjuvant chemotherapy yearly in a hospital (P=0.037). Conclusion: The adherence to CMF treatment guidelines was generally good. Simultaneous radiotherapy did not affect the median RDI of CMF. G-CSF had no impact on the median RDI but patient volume did influence the RDI.

Original language	English
Pages (from-to)	581-590
Number of pages	10
Journal	Journal of cancer research and clinical oncology
Volume	130
Issue number	10
DOIs	https://doi.org/10.1007/s00432-004-0583-6
Publication status	Published - Oct-2004
Event	38th Annual Meeting of the American-Society-of-Clinical-Oncology - Duration: 18-May-2002 → 21-May-2002

Keywords

breast cancer
chemotherapy
guideline
pattern of care
radiotherapy
relative dose intensity
DOSE INTENSITY
EARLY-STAGE
5-FLUOROURACIL CMF
RADIATION-THERAPY
CONSERVATIVE SURGERY
CYCLOPHOSPHAMIDE
METHOTREXATE
RADIOTHERAPY
MANAGEMENT
TRIAL

Access to Document

10.1007/s00432-004-0583-6

Handle.net

Persistent link

Cite this

@article{744884484fb44e2aad7a8b803234a51e,

title = "Quality of adjuvant CMF chemotherapy for node-positive primary breast cancer: a population-based study",

abstract = "Purpose: Adjuvant 'classical' oral cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) has long been the mainstay of adjuvant chemotherapy for premenopausal breast cancer patients. The Comprehensive Cancer Center North Netherlands (CCCN) breast cancer working group performed a retrospective audit of treatment guideline adherence and quality of CMF in hospitals in the CCCN area. Methods: The CMF treatment data of 251 consecutive axillary lymph node-positive breast cancer patients 3 patients/year (P=0.014) were treated by one specialist or >10 patients classified for adjuvant chemotherapy yearly in a hospital (P=0.037). Conclusion: The adherence to CMF treatment guidelines was generally good. Simultaneous radiotherapy did not affect the median RDI of CMF. G-CSF had no impact on the median RDI but patient volume did influence the RDI.",

keywords = "breast cancer, chemotherapy, guideline, pattern of care, radiotherapy, relative dose intensity, DOSE INTENSITY, EARLY-STAGE, 5-FLUOROURACIL CMF, RADIATION-THERAPY, CONSERVATIVE SURGERY, CYCLOPHOSPHAMIDE, METHOTREXATE, RADIOTHERAPY, MANAGEMENT, TRIAL",

author = "M Schaapveld and {de Vries}, EGE and {van der Graaf}, WTA and R Otter and PHB Willemse",

year = "2004",

month = oct,

doi = "10.1007/s00432-004-0583-6",

language = "English",

volume = "130",

pages = "581--590",

journal = "Journal of cancer research and clinical oncology",

issn = "0171-5216",

publisher = "Springer",

number = "10",

note = "38th Annual Meeting of the American-Society-of-Clinical-Oncology ; Conference date: 18-05-2002 Through 21-05-2002",

}

TY - JOUR

T1 - Quality of adjuvant CMF chemotherapy for node-positive primary breast cancer

T2 - 38th Annual Meeting of the American-Society-of-Clinical-Oncology

AU - Schaapveld, M

AU - de Vries, EGE

AU - van der Graaf, WTA

AU - Otter, R

AU - Willemse, PHB

PY - 2004/10

Y1 - 2004/10

N2 - Purpose: Adjuvant 'classical' oral cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) has long been the mainstay of adjuvant chemotherapy for premenopausal breast cancer patients. The Comprehensive Cancer Center North Netherlands (CCCN) breast cancer working group performed a retrospective audit of treatment guideline adherence and quality of CMF in hospitals in the CCCN area. Methods: The CMF treatment data of 251 consecutive axillary lymph node-positive breast cancer patients 3 patients/year (P=0.014) were treated by one specialist or >10 patients classified for adjuvant chemotherapy yearly in a hospital (P=0.037). Conclusion: The adherence to CMF treatment guidelines was generally good. Simultaneous radiotherapy did not affect the median RDI of CMF. G-CSF had no impact on the median RDI but patient volume did influence the RDI.

AB - Purpose: Adjuvant 'classical' oral cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) has long been the mainstay of adjuvant chemotherapy for premenopausal breast cancer patients. The Comprehensive Cancer Center North Netherlands (CCCN) breast cancer working group performed a retrospective audit of treatment guideline adherence and quality of CMF in hospitals in the CCCN area. Methods: The CMF treatment data of 251 consecutive axillary lymph node-positive breast cancer patients 3 patients/year (P=0.014) were treated by one specialist or >10 patients classified for adjuvant chemotherapy yearly in a hospital (P=0.037). Conclusion: The adherence to CMF treatment guidelines was generally good. Simultaneous radiotherapy did not affect the median RDI of CMF. G-CSF had no impact on the median RDI but patient volume did influence the RDI.

KW - breast cancer

KW - chemotherapy

KW - guideline

KW - pattern of care

KW - radiotherapy

KW - relative dose intensity

KW - DOSE INTENSITY

KW - EARLY-STAGE

KW - 5-FLUOROURACIL CMF

KW - RADIATION-THERAPY

KW - CONSERVATIVE SURGERY

KW - CYCLOPHOSPHAMIDE

KW - METHOTREXATE

KW - RADIOTHERAPY

KW - MANAGEMENT

KW - TRIAL

U2 - 10.1007/s00432-004-0583-6

DO - 10.1007/s00432-004-0583-6

M3 - Article

SN - 0171-5216

VL - 130

SP - 581

EP - 590

JO - Journal of cancer research and clinical oncology

JF - Journal of cancer research and clinical oncology

IS - 10

Y2 - 18 May 2002 through 21 May 2002

ER -

Quality of adjuvant CMF chemotherapy for node-positive primary breast cancer: a population-based study

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this